Specific Biologics Inc., a venture-backed, early-stage genome editing company, recently announced it has appointed Steven Kanner, PhD, as an Independent Director. The appointment coincides with renewed investment from Lumira Ventures and adMare BioInnovations to advance the preclinical development of therapeutics based on Specific's proprietary Dualase® platform gene editors.
Specific Biologics is an OBIO® member, an alumnus of our BDSP™, CAAP® , H2BB™ and WiHI programs, and presented at the OBIO® Investment Summit.